3 Things You Need to Know
Standard of care
Is of the essence
Nick: Patient Survivor
The day after his graduation from San Diego State University, Nick was diagnosed with a recurrence of his malignant meningioma. Nick knew he wasn’t going to have a lot of options, but we had just opened a Phase 0 clinical trial for this exact indication.
Tumors We Treat
As the Ivy Brain Tumor Center grows, every patient, regardless of diagnosis or stage of the brain tumor, will have the option to enroll in a Phase 0 clinical trial.
Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma
Also known as ‘secondary’ brain tumors; originate from cancer in another part of the body
Primary brain tumors derived from the lining of the brain, known as the meninges
Arises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord
Arises from small nests of cells near the pituitary stalk at the base of the skull, near the pituitary gland, third ventricle, and optic nerve
Occurs in the pineal region of the brain that may or may not involve the pineal gland
A COMMUNITY OF CAREGIVERS
Woman of the Week Podcast: Catherine Ivy
Catherine Ivy, who lost her husband a decade ago to a devastating and sudden brain cancer, shares her personal journey of grief and purpose, which led to the founding of the Ivy Brain Tumor Center at the Barrow Neurological Institute.
Ivy Brain Tumor Center and SonALAsense to Test Novel Drug-Device Combination for Glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.
Could Karyopharm’s Newly Approved Multiple Myeloma Drug Also Work In Glioblastoma?
The Ivy Brain Tumor’s goal is to try to speed advances into the clinic by testing potential therapies on tumor samples taken from patients who are currently battling glioblastoma—an approach its researchers hope will shed some light on the potential of Karyopharm’s new drug in treating the disease.